| Project/Area Number |
15H04308
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | University of Toyama |
|---|
Principal Investigator |
Kishi Hiroyuki 富山大学, 大学院医学薬学研究部(医学), 准教授 (60186210)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小澤 龍彦 富山大学, 大学院医学薬学研究部(医学), 助教 (10432105)
村口 篤 富山大学, 大学院医学薬学研究部(医学), 名誉教授 (20174287)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HAMANA Hiroshi 富山大学, 大学院医学薬学研究部(医学), 客員准教授 (90551549)
NISHIKAWA Hiroyoshi 国立がん研究センター, 先端医療開発センター, 免疫TR分野長 (10444431)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Keywords | Tumor / T cells / T cell receptor / HLAハプロタイプ / 腫瘍浸潤リンパ球 / TCR / T細胞受容体 / 免疫学 / 抗腫瘍効果 / HLA / ハプロタイプ / 癌 / Ｔ細胞 / 単一細胞解析 |
|---|
| Outline of Final Research Achievements |
T cells play important roles to suppress cancer generation in vivo. Recently, cancer therapy using T cells has been studied. T cells recognize the complex of cancer antigens and HLA molecules on cancer cells and kill them. The structure of HLA molecules are different in individual persons and T cells from a person whose HLA haplotype is different from a patient's HLA haplotype can not be used for the treatment of the patient. Major Japanese populations have HLA-A2 or A24 molecules. Thus, T cells recognizing cancer antigens in the context of HLA-A2 or A24 are studied, but those recognizing other HLA molecules are not. In this study, we have developed the method to find cancer-specific T cells independently of HLA haplotypes.
|
